Vitrupath Products and Services
Welcome to Vitrupath
Return to the introduction on the home page
The Vitrupathknowledgequest site uses advanced analytical lenses and perspectives to answer questions, analyze data, review uploaded information, and support clinical, medical, behavioral, research, biotechnology, technology and other initiatives.
Foundational Simplified Lense for Care, Diagnostics, Therapeutics, Research, Applied Policy Analysis and Development, Program Management, Innovation, Data Analytics, and other synergies
S-adenosyl methylene cysteine( S-adenosyl Hcy, SAH, SA Hcy) < 0.012 µm/L,
methylene cysteine (Hcy) < 6 µm/L statistically toward 3.7 µm/L,
NAD+/NADH ratio 3/1 to 10/1 in tissue,
NAD+/NADH ratio 60/1 to 700/1 in cytoplasmic compartmetns,
NAD+/NMN ratio at least 1 or higher to repress SARM1,
Assuring NMNAT2 which converts NMN to NAD+,
Repression of SARM1, CD38 and CD157 prevent NADase activity,
NADase activity is a component of advancing disease,
NADases catabolize NAD+ and promote Wallerian Degeneration,
NAD+/NADH ratio underlies the physiological/clinical anion gap,
NAD+/NADH ratio powers physiological like a battery,
NAD+/NADH ratio helps load hydrogen anion onto NAD+ and other redox carriers
such as NAD/NADH, NADP+/NADPH, FAD/FADH2, CoQ/CoQH2, PQQ/PQQH2,
Repressing Aerobic Glycolysis therapeutically (PIM2/PKM2/HK2/NEK2/MAT2A/mTorc1/HIF1/Aryl hydrocarbon receptor/pollution/EMF exposure, phosphofructokinase 2, phosphofrucktokinase L, ALDH18A2, other),
tmao intervened and repressed during each intervention and proactively,
Repressing inhibitors of PEMT (SAH, HCY, IDO, Methylglyoxal, CRP, Nitrosamine, tmao, others),
CRISPR, Cas12a2, PROTAC, CAR T, Choline Kinase Alpha Inhibitors,
G quadruplex stabilizers/disruptors, Reviewpoint Kinase Modulation, CK2 inhibitors,
Prioritize FOX1 promoting of Sestrin and TSC2 to Promote mTorc2 while represing mTorc1,
Prioritize mTORC2 promoting of mitochondria association with endoplasm reticulum, MAM membrane,
Prioritize the only known habitat for PEMT2 and PEMT3, MAM Membrane,
Assuring PEMT2 L and PEMT3 L (beginning at conclusion of gestation) to regulate PEMT1 S ( at conception).
Assuring FOX3 regulation of stemness reserves,
Modulating PAX availability to determine if original mitotic source in mitosis reenters stemenss reserve,
= 99.998+ percent decrease in risk for all cause nonoptimal outcomes (risk for nonptimal clinical risk, nonoptimal behavior, detrimental aspects of aging, risk for becoming a victimizer, risk of being victimized, and risk for deterioration of the neurological basis of social behavior)